B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels

Objectives. To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels.

Bibliographic Details
Main Authors: Lazarus, Mark N., Turner-Stokes, Tabitha, Chavele, Konstantia-Maria, Isenberg, David A., Ehrenstein, Michael R.
Format: Online
Language:English
Published: Oxford University Press 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380246/
id pubmed-3380246
recordtype oai_dc
spelling pubmed-33802462012-06-21 B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels Lazarus, Mark N. Turner-Stokes, Tabitha Chavele, Konstantia-Maria Isenberg, David A. Ehrenstein, Michael R. Clinical Science Objectives. To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels. Oxford University Press 2012-07 2012-02-15 /pmc/articles/PMC3380246/ /pubmed/22337941 http://dx.doi.org/10.1093/rheumatology/ker526 Text en © The Author(s) 2012. Published by Oxford University Press on behalf of The British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Lazarus, Mark N.
Turner-Stokes, Tabitha
Chavele, Konstantia-Maria
Isenberg, David A.
Ehrenstein, Michael R.
spellingShingle Lazarus, Mark N.
Turner-Stokes, Tabitha
Chavele, Konstantia-Maria
Isenberg, David A.
Ehrenstein, Michael R.
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
author_facet Lazarus, Mark N.
Turner-Stokes, Tabitha
Chavele, Konstantia-Maria
Isenberg, David A.
Ehrenstein, Michael R.
author_sort Lazarus, Mark N.
title B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
title_short B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
title_full B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
title_fullStr B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
title_full_unstemmed B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
title_sort b-cell numbers and phenotype at clinical relapse following rituximab therapy differ in sle patients according to anti-dsdna antibody levels
description Objectives. To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels.
publisher Oxford University Press
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380246/
_version_ 1611538373335318528

Similar Items